Clinical trial
A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced…
NCT00089726 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00089726 |
|---|---|
| Title | A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) With and Without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell Lung Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Carcinoma, Non-Small-Cell Lung |
| Intervention type | Biological, Drug |
| Interventions | CG8123, Cyclophosphamide |
| Enrollment | 100 |
| Start date | Mar 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Aug 12, 2004 |
| Last update posted | Dec 24, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: